Market Overview

The Adagrasib market is predicted to develop at a compound annual growth rate (CAGR) of XX% from 2024 to 2034, when it is projected to reach USD XX Million, based on an average growth pattern. The market is estimated to reach a value of USD XX Million in 2024.

SOURCE: We Market Research

Adagrasib is a medication used in targeted therapy that blocks KRAS G12C, a particular kind of mutant protein. This mutation is frequently detected in some cancer types, including colorectal and non-small cell lung cancer (NSCLC). Adagrasib functions by preventing the mutant KRAS protein from acting, which is essential in fostering the development of cancer. Adagrasib works to slow down or stop the proliferation of cancer cells that carry the KRAS G12C mutation by blocking this protein. It is being investigated in clinical studies for its efficacy and safety in treating various kinds of tumors, and it represents a potential strategy in targeted cancer therapy.

Mirati Therapeutics produced the oral small-molecule KRAS inhibitor Adagrasib (MRTX849). KRAS mutations make up about 85% of all RAS family mutations and are extremely prevalent in cancer. However, because of their strong affinity for GTP and GDP and because they lack a well-defined binding site, the creation of KRAS inhibitors has proven difficult. Adagrasib suppresses KRAS-dependent signaling by targeting the cysteine 12 residue of KRASG12C, one of the most prevalent KRAS mutations. Adagrasib demonstrated anti-tumor effects in a phase I/IB clinical research including patients with advanced solid tumors with mutations in KRASG12C (NCT03785249). Phase II of the same trial demonstrated that adagrasib was effective without additional safety signals in patients with non-small-cell lung cancer (NSCLC) with a mutation in the KRASG12C gene. 

Market Scope

Adagrasib Industry: Dynamics & Restrains

We Market Research: Adagrasib Dashboard

Our marketing platform offers a comprehensive dashboard that provides clients with valuable insights into market trends over the years. Included below is a sample image of our dashboard, and specific PDF logins will be furnished to grant access to this insightful tool.

Adagrasib Segmentation

Market- By Indication Analysis

By Indication, the Adagrasib Market is Categories into Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Other Solid Tumors. The Non-Small Cell Lung Cancer (NSCLC) segment accounts for the largest share of around 68% in 2024.

Adagrasib is used to treat non-small cell lung cancer (NSCLC) because of its potency against certain genetic alterations, such as KRAS G12C, which is frequently present in NSCLC patients. Adagrasib is a viable treatment option for individuals with NSCLC who have this genetic alteration because of its focused suppression of this mutation, which lowers tumor growth.

The following segments are part of an in-depth analysis of the global Adagrasib market:

Adagrasib Industry: Regional Analysis

North America Market Forecast

North America dominate the Adagrasib Market with the highest revenue generating market with share of more than 47%. Adagrasib is widely utilized in the treatment of NSCLC patients, owing to the high frequency of KRAS G12C mutations, particularly in the United States and Canada. Adagrasib's use in this arena has been accelerated by the FDA's approval of the medicine for NSCLC patients with KRAS G12C mutations.

Europe Market Statistics

Europe is the second largest region in Adagrasib market, due the factors driving market expansion include increased awareness of precision medicine, favorable government initiatives supporting cancer research, and the presence of significant pharmaceutical companies creating novel medicines such as Adagrasib. Furthermore, connections between academic institutions and pharmaceutical businesses help to strengthen research activities in the region.

Asia Pacific Market Forecasts

Asia Pacific is expected to be the fastest-growing regional segment of the Adagrasib market during the forecast period. The Adagrasib market in Asia Pacific region is fueled by factors such as a huge population base, rising cancer incidence, and improved healthcare infrastructure. Furthermore, rising healthcare expenditure, increased investments in the biotechnology and pharmaceutical sectors, and expanding knowledge about customized medicine all contribute to market growth in countries such as China, India, and Japan.

Key Market Players        

The Adagrasib Market is dominated by a few large companies, such as

·         Mirati Therapeutics

·         Amgen

·         Other

1.      Global Adagrasib Market Introduction and Market Overview

1.1.    Objectives of the Study

1.2.    Global Adagrasib Market Scope and Market Estimation

1.2.1. Global Adagrasib Overall Market Size, Revenue (US$ Mn), Market CAGR (%), Market forecast (2023 - 2034)

1.2.2. Global Adagrasib Market Revenue Share (%) and Growth Rate (Y-o-Y) from 2019 - 2034

1.3.    Market Segmentation

1.3.1. Component of Global Adagrasib Market

1.3.2. Technology of Global Adagrasib Market

1.3.3. Distribution Channel of Global Adagrasib Market

1.3.4. Region of Global Adagrasib Market

2.      Executive Summary

2.1.    Global Adagrasib Market Industry Trends under COVID-19 Outbreak

2.1.1. Global COVID-19 Status Overview

2.1.2. Influence of COVID-19 Outbreak on Global Adagrasib Market Industry Development

2.2.    Market Dynamics

2.2.1. Drivers

2.2.2. Limitations

2.2.3. Opportunities

2.2.4. Impact Analysis of Drivers and Restraints

2.3.    Pricing Trends Analysis & Average Selling Prices (ASPs)

2.4.    Key Mergers & Acquisitions, Expansions, JVs, Funding / VCs, etc.

2.5.    Porter’s Five Forces Analysis

2.5.1. Bargaining Power of Suppliers

2.5.2. Bargaining Power of Buyers

2.5.3. Threat of Substitutes

2.5.4. Threat of New Entrants

2.5.5. Competitive Rivalry

2.6.    Value Chain / Ecosystem Analysis

2.7.    Russia-Ukraine War Impacts Analysis

2.8.    Economic Downturn Analysis

2.9.      Market Investment Opportunity Analysis (Top Investment Pockets), By Segments & By Region

3.      Global Adagrasib Market Estimates & Historical Trend Analysis (2019 - 2023)

4.      Global Adagrasib Market Estimates & Forecast Trend Analysis, by INDICATION

4.1.    Global Adagrasib Market Revenue (US$ Mn) Estimates and Forecasts, by INDICATION, 2019 to 2034

4.1.1. Non-Small Cell Lung Cancer (NSCLC)

4.1.2. Colorectal Cancer

4.1.3. Other Solid Tumors

5.      Global Adagrasib Market Estimates & Forecast Trend Analysis, by Treatment Type

5.1.    Global Adagrasib Market Revenue (US$ Mn) Estimates and Forecasts, by Treatment Type, 2019 to 2034

5.1.1. Monotherapy

5.1.2. Combination Therapy

6.      Global Adagrasib Market Estimates & Forecast Trend Analysis, by Distribution Channel

6.1.    Global Adagrasib Market Revenue (US$ Mn) Estimates and Forecasts, by Distribution Channel, 2019 to 2034

6.1.1. Hospital Pharmacies

6.1.2. Retail Pharmacies

6.1.3. Online Pharmacies

7.      Global Adagrasib Market Estimates & Forecast Trend Analysis, by Region

7.1.    Global Adagrasib Market Revenue (US$ Mn) Estimates and Forecasts, by Region, 2019 to 2034

7.1.1. North America

7.1.2. Europe

7.1.3. Asia Pacific

7.1.4. Middle East & Africa

7.1.5. South America

8.      North America Adagrasib Market: Estimates & Forecast Trend Analysis

8.1.    North America Adagrasib Market Assessments & Key Findings

8.1.1. North America Adagrasib Market Introduction

8.1.2. North America Adagrasib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

8.1.2.1.   By INDICATION

8.1.2.2.   By Treatment Type

8.1.2.3.   By Distribution Channel

8.1.2.4.   By Country

8.1.2.4.1.     The U.S.

8.1.2.4.2.     Canada

8.1.2.4.3.     Mexico

9.      Europe Adagrasib Market: Estimates & Forecast Trend Analysis

9.1.    Europe Adagrasib Market Assessments & Key Findings

9.1.1. Europe Adagrasib Market Introduction

9.1.2. Europe Adagrasib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

9.1.2.1.   By INDICATION

9.1.2.2.   By Treatment Type

9.1.2.3.   By Distribution Channel

9.1.2.4.        By Country

9.1.2.4.1.     Germany

9.1.2.4.2.     U.K.

9.1.2.4.3.     France

9.1.2.4.4.     Italy

9.1.2.4.5.     Spain

9.1.2.4.6.     Russia

9.1.2.4.7.     Rest of Europe

10.  Asia Pacific Adagrasib Market: Estimates & Forecast Trend Analysis

10.1.  Asia Pacific Market Assessments & Key Findings

10.1.1.   Asia Pacific Adagrasib Market Introduction

10.1.2.   Asia Pacific Adagrasib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

10.1.2.1.    By INDICATION

10.1.2.2.    By Treatment Type

10.1.2.3.    By Distribution Channel

10.1.2.4.    By Country

10.1.2.4.1. China

10.1.2.4.2. Japan

10.1.2.4.3. India

10.1.2.4.4. Australia

10.1.2.4.5. South Korea

10.1.2.4.6. ASEAN

10.1.2.4.7. Rest of Asia Pacific

11.  Middle East & Africa Adagrasib Market: Estimates & Forecast Trend Analysis

11.1.  Middle East & Africa Market Assessments & Key Findings

11.1.1.   Middle East & Africa Adagrasib Market Introduction

11.1.2.   Middle East & Africa Adagrasib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

11.1.2.1.    By INDICATION

11.1.2.2.    By Treatment Type

11.1.2.3.    By Distribution Channel

11.1.2.4.    By Country

11.1.2.4.1. U.A.E.

11.1.2.4.2. Saudi Arabia

11.1.2.4.3. Egypt

11.1.2.4.4. South Africa

11.1.2.4.5. Rest of Middle East & Africa

12.  South America Adagrasib Market: Estimates & Forecast Trend Analysis

12.1.  South America Market Assessments & Key Findings

12.1.1.   South America Adagrasib Market Introduction

12.1.2.   South America Adagrasib Market Size Estimates and Forecast (US$ Million) (2019 – 2034)

12.1.2.1.    By INDICATION

12.1.2.2.    By Treatment Type

12.1.2.3.    By Distribution Channel

12.1.2.4.    By Country

12.1.2.4.1. Brazil

12.1.2.4.2. Argentina

12.1.2.4.3. Colombia

12.1.2.4.4. Rest of South America

13.  Competition Landscape

13.1.  Global Adagrasib Market Competition Matrix & Benchmarking, by Leading Players / Innovators / Emerging Players / New Entrants

13.2.  Global Adagrasib Market Competition White Space Analysis, By Distribution Channel

13.3.  Global Adagrasib Market Competition Heat Map Analysis, By Distribution Channel

13.4.  Global Adagrasib Market Concentration & Company Market Shares (%) Analysis, 2022

14.  Company Profiles

14.1.                     Mirati Therapeutics

14.1.1.   Company Overview & Key Stats

14.1.2.   Financial Performance & KPIs

14.1.3.   Product Portfolio

14.1.4.   Business Strategy & Recent Developments

* Similar details would be provided for all the players mentioned below 

14.2.      Amgen

14.3.      Others

15.  Research Methodology

15.1.  External Transportations / Databases

15.2.  Internal Proprietary Database

15.3.  Primary Research

15.4.  Secondary Research

15.5.  Assumptions

15.6.  Limitations

15.7.  Report FAQs

16.  Research Findings & Conclusion